Overview
Patients with liver cirrhosis are at high risk of developing hepatocellular carcinoma (HCC) which implies significant mortality. At present current surveillance methods detect hepatocellular carcinomas at a late stage resulting in few treatment options for patients and, in the majority of cases, premature death.
The goal of this study is to implement Elecsys® GAAD in real-world hepatocellular carcinoma surveillance for those with liver cirrhosis.
The main questions it aims to answer are:
- Does the introduction of the Elecsys® GAAD algorithm to the surveillance pathway increase early detection of HCC?
- Does the introduction of the Elecsys® GAAD algorithm to the surveillance pathway reduce false positive tests and unnecessary confirmatory investigations?
- Does the new surveillance pathway improve adherence?
Researchers will compare Elecsys® GAAD with standard of care tests to see if it results in earlier detection of hepatocellular carcinoma and will explore potential improvements to the surveillance pathway.
Eligibility
Inclusion Criteria:
• Patients with known liver cirrhosis referred into or already under hepatocellular
carcinoma surveillance
Exclusion Criteria:
- Pregnancy/breast-feeding.
- Patients who do not have liver cirrhosis
- Patients who already have hepatocellular carcinoma
- Any patient who is unable to understand, retain and weigh information to make an
informed decision, will be excluded from the study. The investigators will use every
opportunity, including tele-interpretation services to minimise this from happening.